Status:
COMPLETED
Intra-individual Comparison of Conventional and Digital PET/CT Scanners
Lead Sponsor:
Isala
Collaborating Sponsors:
Philips Healthcare
Conditions:
Breast Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of ...
Detailed Description
There will be a single injection of the PET radiopharmaceutical FDG, followed by a conventional PET/CT scan and a digital PET scan, in this order or vice versa.
Eligibility Criteria
Inclusion
- Inclusion criteria
- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- referred to Isala for a clinically indicated FDG-PET/CT scan
- suspected or proven lung cancer, esophageal cancer, breast cancer or miscellaneous cancer, either as a primary diagnosis or follow-up study
- signed informed consent
- Exclusion criteria
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- age \< 18 years
- incapacitated adults
- prisoners
- pregnant patients
- unable to undergo two consecutive PET/CT scans
Exclusion
Key Trial Info
Start Date :
January 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2019
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT03457506
Start Date
January 8 2018
End Date
September 13 2019
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Isala
Zwolle, Overijssel, Netherlands, 8025AB